Survival Similar for Black, White Prostate Cancer Patients in Clinical Trial Setting
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Aug. 4, 2023 -- For metastatic castration-sensitive prostate cancer (mCSPC), overall survival and progression-free survival are similar for Black and White patients receiving first- or second-generation androgen receptor pathway inhibitors within a clinical trial, according to a study published online Aug. 1 in JAMA Network Open.
Nicolas Sayegh, M.D., from the University of Utah in Salt Lake City, and colleagues conducted a secondary analysis of patient-level data of a prospective phase 3 randomized clinical trial including patients with newly diagnosed mCSPC to compare survival outcomes by race. Patients receiving androgen deprivation therapy were randomly assigned to receive orteronel 300 mg orally twice daily (experimental group) or bicalutamide 50 mg orally daily (control group). Data were included for 1,313 participants: 10 and 82 percent identified as Black and White, respectively, with an equal racial distribution between the treatment groups.
The researchers found that Black and White patients had similar median progression-free survival (2.3 years versus 2.9 years) and overall survival (5.5 years versus 6.3 years) at a median follow-up of 4.9 years. After adjustment for known prognostic factors, the multivariable analysis confirmed similar progression-free and overall survival. There was no interaction observed between race and treatment.
"These results support the hypothesis that equitable access to care as available in a clinical trial setting negates disparities in outcomes previously associated with Black patient populations," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Activity Tracker, Scale Plus Phone App May Aid Weight Loss
THURSDAY, May 16, 2024 -- Weight loss is similar for individuals using a wireless feedback system (WFS) that provides daily information on lifestyle change and weight loss versus...
Male, Female V1421 Carriers Face Similar Risk for Heart Failure Hospitalization
THURSDAY, May 16, 2024 -- Male and female V1421 carriers face a similar and substantial risk for heart failure hospitalization, according to a study published online May 12 in the...
Radiomics Features Can Identify Destabilizing Meniscal Tears
THURSDAY, May 16, 2024 -- Radiomics features can help identify incident destabilizing meniscal tears, according to a study published online May 15 in the Journal of Orthopaedic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.